At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06946927Phase 1RecruitingMonitorUpdated 12mo ago · Completion was 4mo agoA Phase Ib, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of JMKX001899 in Combination With Other Therapies in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation.
In Brief
A Phase 1 clinical trial evaluating JMKX001899, IN10018, and 2 other interventions for NSCLC (Advanced Non-small Cell Lung Cancer). Currently recruiting, targeting 72 participants across 1 site.
Signals
Detailed Summary
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Study Details
Timeline
Interventions
JMKX001899 tablet administered orally daily.
IN10018 tablet administered orally daily.
IV infusion once every 3 weeks
IV infusion once every 3 weeks, 4 Cycles